# A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer

> **NCT06612151** · PHASE3 · RECRUITING · sponsor: **MediLink Therapeutics (Suzhou) Co., Ltd.** · enrollment: 438 (estimated)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** YL201
- **DRUG:** topotecan hydrochloride for injection

## Key facts

- **NCT ID:** NCT06612151
- **Lead sponsor:** MediLink Therapeutics (Suzhou) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-17
- **Primary completion:** 2027-12-01
- **Final completion:** 2030-12-01
- **Target enrollment:** 438 (ESTIMATED)
- **Last updated:** 2025-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06612151

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06612151, "A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT06612151. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*